Mylan LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.6M
Doctors Paid
284
Transactions
1,599
2024 Total
$588,768
Payment Breakdown by Category
Research$3.4M (73.7%)
Consulting$406,547 (8.8%)
Travel$202,678 (4.4%)
Food & Beverage$16,502 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 266 | 73.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $585,266 | 240 | 12.6% |
| Consulting Fee | $406,547 | 102 | 8.8% |
| Travel and Lodging | $202,678 | 285 | 4.4% |
| Food and Beverage | $16,502 | 700 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $10,000 | 1 | 0.2% |
| Education | $1,995 | 5 | 0.0% |
Payments by Type
Research
$3.4M
266 transactions
General
$1.2M
1,333 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | $948,409 | 0 | 102 |
| Retrospective Patient Level Data Collection for Subjects in FondaKIDS III Study | $800,000 | 0 | 2 |
| MELO-TFZ-2002 | $527,324 | 0 | 3 |
| AED Pregnancy Registry | $340,000 | 0 | 4 |
| RADARS | $249,201 | 0 | 8 |
| 11932904 | $176,800 | 0 | 3 |
| PRECISION Trial Biomarker Sub study | $97,061 | 0 | 1 |
| A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema | $76,007 | 1 | 25 |
| MYL-1701P | $54,923 | 3 | 11 |
| NCT03502070 | $47,847 | 0 | 27 |
| MELO-TFZ-2001 | $44,237 | 0 | 3 |
| MELO-TFZ-2003 | $38,758 | 0 | 3 |
| Mycophenolate Pregnancy Exposure Registry | $6,750 | 4 | 8 |
| A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D With NovoLog in Type 1 Diabetes Mellitus Patients; Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus in Type 1 Diabetes Mellitus (T1DM) Patients | $5,525 | 1 | 1 |
| Antiretroviral Pregnancy Registry (APR) | $3,629 | 3 | 42 |
| REV-3001-A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY OF NEBULIZED REVEFENACIN INHALATION SOLUTION IN CHINESE SUBJECTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | $3,589 | 0 | 1 |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR) | $1,100 | 5 | 21 |
| Evaluating the Abuse Potential of NEURONTIN When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience - A9451180 | $295.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 12
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Elsie Diaz - Schroeder, Md, MD | Pulmonary Disease | Caguas, PR | $11.21 | $0 |
| Dr. Lourdes Pedraza, Md, MD | Pediatric Pulmonology | San Juan, PR | $11.18 | $0 |
| Angel Perez, M.d, M.D | Pulmonary Disease | Manati, PR | $11.11 | $0 |
| Dr. Antonio Saldana De La Rosa, Md, MD | General Practice | Rio Piedras, PR | $10.98 | $0 |
| Dr. Nilsa Freyre, M.d, M.D | Specialist | Santurce, PR | $10.82 | $0 |
| Dr. Margarita Martinez-Cruzado, M.d, M.D | Pediatrics | San Juan, PR | $10.79 | $0 |
| Dr. Zulma Velazquez, M.d, M.D | Pediatrics | Las Piedras, PR | $10.68 | $0 |
| Francisco Suarez Lozada, M.d, M.D | Plastic Surgery within the Head & Neck | Mayaguez, PR | $10.12 | $0 |
Ad
Top Products
- ARIXTRA $800,000
- Meloxicam $610,320
Associated Products (7)
- ARIXTRA $800,000
- Levothyroxine Sodium $221,000
- Wixela Inhub $108,832
- Fentanyl $97,728
- EFFEXOR $28,879
- CLOZAPINE $25,298
- NORVASC $13,332
Payment Categories
- Food & Beverage $16,502
- Consulting $406,547
- Travel & Lodging $202,678
- Research $3.4M
About Mylan LLC
Mylan LLC has made $4.6M in payments to 284 healthcare providers, recorded across 1,599 transactions in the CMS Open Payments database. In 2024, the company paid $588,768. The top product by payment volume is ARIXTRA ($800,000).
Payments were distributed across 55 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($199,344 to 5 doctors).
Payment categories include: Food & Beverage ($16,502), Consulting ($406,547), Research ($3.4M), Travel & Lodging ($202,678).
Mylan LLC is associated with 7 products in the CMS Open Payments database, including ARIXTRA, Levothyroxine Sodium, and Wixela Inhub.